Drugs / Cr-EDTA
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01588756 | Oct 2010 → May 2015 | chronic kidney disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cr-EDTA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01588756 ↗ |
| Modality | Diagnostic / imaging agent | “Rigorous assessment of GFR requires the measurement of urinary or plasma clearance of an ideal exogenous filtration marker which is either non-radioactive (inulin, iothalamate,...” NCT01588756 ↗ |
| Route | Intravenous | “AcSDKP-NH2 Cr-EDTA, Once intravenous administration of 100 µg or less” NCT01588756 ↗ |